The world's first and only single entry EPICARDIAL procedure for the treatment of atrial fibrillation related stroke risk and blood pressure related heart attack risk
Patented device
Left Atrial Appendage Seclusion Tool
One-size fits all device, completely repositionable. One-size-fits all economics.
The only single access epicardial LAA closure. No need for Heparin, nor for post procedure oral anticoagulant (OAC).
Patented hollow structure ligation. Patented electrolocation for less invasive and accurate closure.
Developed in partnership with the Mayo Clinic.
Alongside the Mayo Clinic, Aegis Medical Innovations has developed the world's first, and patented, epicardial only LAA seclusion tool and procedure to address the devastating atrial fibrillation risk that 5 million Americans face. It is estimated that 35-37.5 million patients globally suffer from atrial fibrillation. 90% of stroke causing clots that come from the heart are formed in the LAA. This population is 5x more likely to have a stroke. They also are at a 5x greater risk of heart failure than their peers.
A single trained professional can tie off and close the LAA in 15 minutes with our tool, Sierra.
Our epicardial seclusion approach avoids many complications resulting from endocardial procedures.
Epicardial procedures may have collateral benefits to patients including isolating the LAA and lowering blood pressure.
Given procedural and ongoing risks associated with peer devices, a safe, more reliable, less demanding LAA seclusion tool is desperately needed.
Research Report
First-in-Human Percutaneous Epicardial-Only Left Atrial Appendage Closure Using Sierra Left Atrial Appendage Ligation System
This article presents the first-in-human study on a groundbreaking device, the Sierra Left Atrial Appendage Ligation System, offering a new approach to stroke prevention in patients with atrial fibrillation. Explore how this innovative method ensures safety and effectiveness with promising outcomes.
